Eli Lilly (LLY) has been in the news with a slew of market-moving developments. The company's strong Q1 performance saw sales increase by
45% due to demand for its weight loss drug, but the stock fell after lowering its profit outlook following a cancer treatment deal. Situations worsened when CVS decided to drop
Zepbound coverage, triggering a drastic drop in share value and causing Lilly to lose a battle to Novo's Wegovy. However,
JP Morgan felt the sell-off was an overreaction. Meanwhile, its GLP-1 wave is doing well, and the CEO appears unfazed by CVS-Novo Nordisk's deal. Furthermore, there is optimism about Lilly's long-term growth and dividend offering possibilities. Execution is anticipated in dealing with potential tariffs on pharmaceuticals. However, concerns regarding valuation and increasing competition led to downgrading by HSBC, but analysts maintain that the backlash was somewhat overdone. The promising results from the oral weight-loss drug trial led to a boost in stock, however, its Q1 EPS missed by 12c. The years ahead will test the company's solvent profitability and response to shifting market dynamics.
Eli Lilly LLY News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Sat, 03 May 2025 13:30:00 GMT -
Rating -2
- Innovation 5
- Information 7
- Rumor -4
